leisure time -WSS

leisure time

author：Wikipedia 2025-08-26 23:46:57 - browse：4

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： ActiGraph execs on goal of drug approvals with digital endpoints

leisure time

WSS

Eye stem cell transplant could help restore vision in injured people

Living with Hashimoto's and celiac disease, and med school, too

Pregnancy discrimination could be enabled by AI

In diabetes hearing, Sanders takes on a new foe: food makers

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Continuity nursing helped my family in our darkest PICU moments

STAT letters to the editor on burnt

Duchenne breakthrough therapy leaves behind pioneering families

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

DIEP, the 'gold standard' of breast reconstruction, is under threat

Pharma patents targeted by Biden in move to slash drug prices

As demand for Covid shots wanes, Moderna seeks its next success

Congress must give Medicare recipients genetic counseling access

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Wikipedia

Patient advocates sound warning on FDA proposal on salt intake

Evacuations in place as 3 wildfires burn in eastern Washington state

Why sickle cell disease is getting the first CRISPR treatment

Beware the threat of staffing cuts at the CDC

Trump's false claims about Georgia's 2020 election long debunked

Trump cancels press conference intended to dispute Georgia election interference charges

Wikipedia

leisure time

hotspot

focus